Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Finance Minister Hears Out LDP Group’s Emergency Proposal on Off-Year Re-Pricing
December 14, 2022
- Japan to Refit R&D Tax Credit System to Boost Incentive; Lower Minimum Deduction Rate, Variable Cap
December 14, 2022
- Japan to Add Age 12-17 for Moderna Boosters in Free Emergency Program
December 14, 2022
- Japan Govt to Purchase Another 1 Million Courses of Xocova
December 14, 2022
- LDP Committee Insists on Better Handling of Innovative Drugs, Unprofitable Meds in Off-Year Re-Pricing
December 13, 2022
- LDP League, MHLW Discussing to Create Forum to Study SaMD Reimbursement
December 13, 2022
- Paper Retraction Won’t Impact Zolgensma Japan Approval, Data Deleted from Label
December 13, 2022
- Yescarta, Breyanzi Clear Panel Review for Second-Line Use
December 13, 2022
- Japan Panel Recognizes 5 More Deaths Possibly Linked to COVID Jabs, 1st for 20s
December 13, 2022
- Japan’s Diet Enacts Bill to Amend Intractable Disease Law
December 13, 2022
- Add New Evaluation Elements in Granting Launch Premiums: Expert Panel
December 12, 2022
- Market Expansion Re-Pricing Has Gone Overboard with Spillover Rule, Experts Say
December 12, 2022
- Revisit PMP Company Criteria to Support Innovation from Foreign Biotechs: Experts
December 12, 2022
- Experts Call for New Drug Pricing Rule for Innovative Medicines, No Objections Raised
December 12, 2022
- 70% of Listed Meds Likely to Face Off-Year Re-Pricing If Prior Threshold Applied: MHLW
December 12, 2022
- Keytruda Gets Orphan Tag for PMBCL in Japan
December 12, 2022
- First Generics for 5 APIs Join NHI Price List, Main Targets Are Nexium/Lexapro
December 9, 2022
- Panel OKs Moderna Boosters for Age 12 and Up
December 9, 2022
- Industry Prods Special Inflation Measure in Off Year, Payers Don’t See Much Need: Chuikyo Hearing
December 8, 2022
- Japan Offers Mpox Vaccines to Columbia for Free
December 8, 2022
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…